Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01594853|
Recruitment Status : Completed
First Posted : May 9, 2012
Results First Posted : August 29, 2018
Last Update Posted : August 29, 2018
|Condition or disease||Intervention/treatment||Phase|
|X-linked Adrenoleukodystrophy||Behavioral: exercise training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Exercise Study of Function and Pathology for Women With X-ALD|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2014|
Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
Behavioral: exercise training
The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
- Change in Maximal Voluntary Contraction of the Hip Flexors From Baseline to End of Training and to Post-training [ Time Frame: Participants are assessed at baseline (visit 1, enrollment), end of training (visit 2, week 12) and post-training (visit 3, week 18). ]Here, we will assess whether the degree of a person's white matter integrity (i.e. for tracts of interest as measured from MRI) predicts their ability to benefit from exercise. Our prediction is that those individuals with preserved white matter integrity will show the greatest improvement in hip flexor strength.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01594853
|United States, Maryland|
|Motion Analysis Lab|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Kathleen M Zackowski, Ph.D.||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|